# A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway

> **NCT05578092** · PHASE1 · TERMINATED · sponsor: **Mirati Therapeutics Inc.** · enrollment: 64 (actual)

## Conditions studied

- Solid Tumor
- Advanced Solid Tumor
- Non Small Cell Lung Cancer
- Colo-rectal Cancer

## Interventions

- **DRUG:** MRTX0902
- **DRUG:** MRTX849

## Key facts

- **NCT ID:** NCT05578092
- **Lead sponsor:** Mirati Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-12-02
- **Primary completion:** 2026-02-03
- **Final completion:** 2026-02-03
- **Target enrollment:** 64 (ACTUAL)
- **Why stopped:** business objectives have changed
- **Last updated:** 2026-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05578092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05578092, "A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05578092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*